Résumés
Résumé
La survie et le développement des tumeurs dépendent d’événements et d’échanges biologiques nutritionnels et respiratoires assurés par le sang et la lymphe. La prolifération tumorale est associée à un accroissement des réseaux vasculaires soit à proximité de la tumeur, soit en intra-tumoral. Les tissus tumoraux sont capables d’augmenter leurs approvisionnements, en fonction de leurs besoins au sein de l’organisme, en orientant et en optimisant le développement des vaisseaux péri-tumoraux. La production par les cellules cancéreuses de facteurs de croissance stimulant la néoformation des vaisseaux lymphatiques constitue une des adaptations responsables de la propagation métastatique. Au cours du développement tumoral, le système lymphatique est considéré dans de nombreux cas de cancers comme la voie primaire de dissémination des métastases. L’étude de la mise en place du système lymphatique et éventuellement de son blocage sont des points importants à considérer en oncologie.
Summary
Survival and development of tumors depends on nutritional and respiratory biological events and exchanges ensured by blood and lymph. Tumor proliferation is associated with an increase in the vascular networks either near the tumor or intra-tumorally. Tumor tissues are able to increase their provisionment according to their needs while directing and optimizing the development of peri-tumoral vessels. The production of growth factors stimulating neo-formation of lymphatic vessels by cancer cells constitutes one of the adaptations responsible for metastatic propagation. During tumor development the lymphatic system is considered in many cases of cancer as the primary means of metastasis dissemination. The study of the lymphatic system setting and ways to block it are important points to consider in oncology.
Parties annexes
Références
- 1. Cunnick GH, Jiang WG, Gomez KF, Mansel RE. Lymphangiogenesis and breast cancer metastasis. Histol Histopathol 2002 ; 17 : 863-70.
- 2. Stacker SA, Achen MG, Jussila L, et al. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2002 ; 2 : 573-83.
- 3. Swartz MA. The physiology of the lymphatic system. Adv Drug Deliv Rev 2001 ; 50 : 3-20.
- 4. Adair TH, Vance GA, Montani JP, Guyton AC. Effect of skin concavity on subcutaneous tissue fluid pressure. Am J Physiol 1991 ; 261: H349-53.
- 5. Jeltsch M, Tammela T, Alitalo K, Wilting J. Genesis and pathogenesis of lymphatic vessels. Cell Tissue Res 2003 ; 314 : 69-84.
- 6. Zarzaur BL, Kudsk KA. The mucosa-associated lymphoid tissue structure, function and derangements. Shock 2001 ; 15 : 411-20.
- 7. Wilting J, Neeff H, Christ B. Embryonic lymphangiogenesis. Cell Tissue Res 1999 ; 297 : 1-11.
- 8. Van der Putte SC. The development of the lymphatic system in man. Adv Anat Embryol Cell Biol 1975 ; 51 : 3-60.
- 9. Wilting J, Papoutsi M, Othman-Hassan K, et al. Development of the avian lymphatic system. Microsc Res Tech 2001 ; 55 : 81-91.
- 10. Aprelikova O, Pajusola K, Partanen J, et al. FLT-4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter. Cancer Res 1992 ; 52 : 746-8.
- 11. Petrova TV, Makinen T, Alitalo K. Signaling via vascular endothelial growth factor receptors. Exp Cell Res 1999 ; 253 : 117-30.
- 12. Hong YK, Lange-Asschenfeldt B, Velasco P, et al. VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins. FASEB J 2004 ; 18 : 1111-3.
- 13. Aprelikova O, Pajusola K, Partanen J, et al. FLT-4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter. Cancer Res 1992 ; 52 : 746-8.
- 14. Nisato RE, Harrison JA, Buser R, et al. Generation and characterization of telomerase-transfected human lymphatic endothelial cells with an extended life span. Am J Pathol 2004 ; 165 : 11-24.
- 15. Banerji S, Ni J, Wang SX, et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 1999 ; 144 : 789-801.
- 16. Prevo R, Banerji S, Ferguson DJ, et al. Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium. J Biol Chem 2001 ; 276 : 19420-30.
- 17. Mouta Carreira C, Nasser SM, di Tomaso E, et al. LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down regulation in human liver cancer and cirrhosis. Cancer Res 2001 ; 61 : 8079-84.
- 18. Breiteneder-Geleff S, Soleiman A, Kowalski H, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 1999 ; 154 : 385-94.
- 19. Hong YK, Foreman K, Shin JW, et al. Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpes virus. Nat Genet 2004 ; 36 : 683-5.
- 20. Partanen TA, Paavonen K. Lymphatic versus blood vascular endothelial growth factors and receptors in humans. Microsc Res Tech 2001 ; 55 : 108-21.
- 21. Zinovieva RD, Duncan MK, Johnson TR, et al. Structure and chromosomal localization of the human homeobox gene Prox1. Genomics 1996 ; 35 : 517-22.
- 22. Oliver G, Sosa-Pineda B, Geisendorf S, et al. Prox 1, a prospero-related homeobox gene expressed during mouse development. Mech Dev 1993 ; 44 : 3-16.
- 23. Kitadai Y, Kodama M, Cho S, et al. Quantitative analysis of lymphangiogenic markers for predicting metastasis of human gastric carcinoma to lymph nodes. Int J Cancer 2005 ; 115 : 388-92.
- 24. Saharinen P, Tammela T, Karkkainen MJ, Alitalo K. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol 2004 ; 25 : 387-95.
- 25. Braat AE, Oosterhuis JW, Moll FC, de Vries JE. Successful sentinel node identification in colon carcinoma using Patent Blue V. Eur J Surg Oncol 2004 ; 30 : 633-7.
- 26. Pepper MS, Tille JC, Nisato R, Skobe M. Lymphangiogenesis and tumor metastasis. Cell Tissue Res 2003 ; 314 : 167-77.
- 27. Smith MC, Luker KE, Garbow JR, et al. CXCR4 regulates growth of both primary and etastatic breast cancer. Cancer Res 2004 ; 64 : 8604-12.
- 28. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 ; 350 : 2335-42.